Collaborative Research Driving New Standards in Hypertension Care

The recognition of Widaplik™, a triple fixed-dose combination for the treatment of hypertension, highlights how collaborative research can shape treatment approaches.

The program was managed globally by The George Institute for Global Health, with RemediumOne contributing from Sri Lanka through local expertise and operational delivery.

Key milestones
1. US FDA approval on 9 June 2024
2. WHO inclusion in the 24th Model List of Essential Medicines (EML) on 5 September 2025

Sri Lanka’s contribution through RemediumOne
1. More than 40% of global enrollment
2. Fully engaged trial sites across Sri Lanka
3. SIM-enabled blood pressure monitoring devices with a 97% return rate
4. Involvement of board-certified and internationally trained investigators
5. Quick access to support services such as laboratory investigations, X-rays, and medical scans
6. Structured follow-up systems to maintain compliance

Trial outcomes
1. Blood pressure control achieved in up to 74% of patients
2. Global objective: increase control rates to 80%, with emphasis on low- and middle-income countries

Acknowledgement
Investigators, hospitals, and participants in Sri Lanka and internationally.
This collaboration demonstrates how global management and local expertise can work together to set new standards in hypertension care at an accelerated pace.